HRPC(600829)

Search documents
人民同泰2024年净利润下降27% 医药批发业务承压
Xi Niu Cai Jing· 2025-04-16 09:18
4月12日,人民同泰发布年报,2024年实现营业收入100.48亿元,同比下降3.29%;实现归母净利润2.13亿元,同比减少27.00%;实现扣非净利润1.99亿元, 降幅扩大至30.86%;基本每股收益为0.36元/股。 2024年,人民同泰批发业务营收为82.28亿元,同比下降4.89%,主要受带量采购常态化、医保控费及市场竞争加剧影响。2024年,人民同泰已新增2200余个 经营品规并强化供应商合作,但毛利空间仍持续收窄,公立医院销售规模缩减叠加客户账期管控趋严,导致收入与利润承压。 | 主要会计数据 | 2024年 | 2023年 | 本期比 上年同 期增减 | 2022 | | --- | --- | --- | --- | --- | | | | | (%) | | | 营业收入 | 10,048,279,393.68 | 10,389,980,124.13 | -3.29 | 9.641.09 | | 归属于上市公司股 | 213,272,260.12 | 292.161.807.26 | -27.00 | 264.47 | | 东的净利润 | | | | | | 归属于上市公司股 | | | ...
人民同泰去年营收100.48亿元,积极承接处方外流市场助零售板块收入增长5.67%
Cai Jing Wang· 2025-04-14 03:08
近日,人民同泰发布2024年财报。披露公司去年营收下降3.29%至100.48亿元,归属净利润下降27%至2.13亿元。 对于净利润减少,公告解释称,一是销售同比降低,利润减少,二是毛利率同比下降,其中批发板块毛利空间收紧; 零售板块品种的销售结构变化,本期 DTP 品种销售占比提高,毛利减少。公司合理控制费用支出,仍无法弥补毛利额 下降导致的净利润减少。 对于医药零售业务,公告介绍,截至报告期末,公司旗下直营门店数量 382 家,其中,哈尔滨市内门店数量为 237 家,市外门店数量为 145 家,会员人数 260 余万人,会员销售占比约 78%。报告期内,公司 DTP 专业药房发展良 好,带动零售业务收入增长,由于行业政策、销售品种结构变化及市场竞争加剧等多重因素影响,零售业务毛利率下 降。 公司以市场需求为导向,强化供应链管理工作,持续优化商品结构。同时,公司积极推行多元化营销策略,优化门店 布局,加强对会员的精准服务,不断提升专业服务能力。 公司加大新品引进力度,多渠道丰富商品品种,构建多元化的大健康品类矩阵,提升商品满足率。此外,公司持续强 化商品品牌力,打造具有竞争力的产品梯队,优化商品采购、调拨及 ...
21健讯Daily|各地医保数据工作组基本完成首次信息发布工作; 博雅生物拟出让博雅欣和80%股权
2 1 Shi Ji Jing Ji Bao Dao· 2025-04-14 01:11
Policy Developments - The National Healthcare Security Administration has established data working groups across all regions, with the aim of enhancing data governance and transparency in healthcare funding [2] Drug and Device Approvals - Jiangsu Tianshili submitted a listing application for the new drug PXT3003, intended for the treatment of Charcot-Marie-Tooth disease type 1A [4] Capital Markets - Ruijian Pharmaceutical completed nearly 100 million RMB in B+ round financing, bringing total financing to over 200 million RMB in less than six months [6] - Weichan Medical announced the completion of several million RMB in angel round financing, aimed at accelerating product development and market entry [7] - Novartis plans to invest $23 billion in the U.S. over the next five years to enhance production capabilities and ensure the domestic supply of critical medications [8] Industry Events - Boya Bio disclosed plans to sell 80% of its subsidiary, Boya Xinha, to focus on its core blood products business, with an initial listing price of 213 million RMB [10] Financial Reports - Pumen Technology reported a revenue of 1.148 billion RMB for 2024, with a net profit of 345 million RMB, reflecting a 5.12% increase [12] - Huaxi Biotechnology's revenue for 2024 was 5.371 billion RMB, down 11.61%, with a net profit of 174 million RMB, down 70.59% [13] - Watson Bio reported a revenue of 2.821 billion RMB for 2024, down 31.41%, with a net profit of 142 million RMB, down 66.10% [14] - Innovation Medical reported a revenue of 816 million RMB for 2024, with a net loss of 93.95 million RMB [15] - People's Tongtai reported a revenue of 10.048 billion RMB for 2024, down 3.29%, with a net profit of 213 million RMB, down 27% [16] - Haizike reported a revenue of 3.721 billion RMB for 2024, with a net profit of 395 million RMB, up 34% [17] - Hainan Haiyao reported a revenue of approximately 999 million RMB for 2024, down 33%, with a net loss of 1.525 billion RMB [18] - Wantai Bio reported a revenue of approximately 2.245 billion RMB for 2024, down 59.25%, with a net profit of 106 million RMB, down 91.49% [19] Public Opinion Alerts - Xinghao Pharmaceutical announced the resignation of director Li Huiqu due to personal reasons, effective April 11, 2025 [21] - Zhaoyan New Drug acknowledged unusual fluctuations in its stock price, linked to a recent FDA plan that may impact the industry [23]
人民同泰2024年财报:净利润下滑27%,医药批发业务承压
Jin Rong Jie· 2025-04-12 04:35
Core Insights - The company reported a total revenue of 10.048 billion yuan in 2024, a year-on-year decrease of 3.29% [1] - The net profit attributable to shareholders was 213 million yuan, down 27.00% year-on-year, while the net profit after deducting non-recurring items was 199 million yuan, a decline of 30.86% [1] Revenue Breakdown - The pharmaceutical wholesale business generated 8.228 billion yuan in revenue, reflecting a decline of 4.89% due to normalized volume-based procurement, medical insurance cost control, and intensified market competition [4] - The pharmaceutical retail business achieved a revenue of 1.691 billion yuan, marking a growth of 5.67%, with 382 direct stores and over 2.6 million members, although the gross margin decreased due to industry policy changes and market competition [5] Business Performance - The medical services and logistics distribution sectors showed stable development, with the medical service business seeing over 105,000 outpatient visits, and the logistics center handling 5.07 million items throughout the year [6] - Despite the stable performance in medical services and logistics, their contributions to overall revenue and profit were limited, failing to offset the decline in the wholesale business [6] Strategic Responses - The company has implemented strategies such as enhancing marketing efforts, upgrading product matrices, and deepening supplier collaboration to address challenges in the wholesale business [4] - In the retail sector, the company focused on supply chain management, optimizing product structure, and diversifying marketing strategies to boost revenue, particularly through the development of DTP specialty pharmacies [5]
上市公司动态 | 万泰生物2024年净利润降九成,紫金矿业一季度净利同比增62%
Sou Hu Cai Jing· 2025-04-12 04:06
免疫诊断方向,已基本完成覆盖高中低通量的仪器布局,包括三款全自动化学发光免疫分析仪 (Caris200、Wan200+、Wan100)以及配套115项试剂,满足临床检验各种应用场景的核心需求,公司 国产自研的一款高速化学发光免疫分析仪Wan600开发已经进入行政审批阶段,将进一步提升检测效率 和准确性。生化诊断方向,公司推出一款高通量全自动生化分析仪WanBC2800。 西部矿业2024年净利润同比增长5% -- 重点要闻– 万泰生物2024年净利润1.06亿元 万泰生物(603392.SH)发布2024年年报,致力于为我国临床医疗体系提供优质、全面的体外诊断解决方 案。2024年营业收入为22.45亿元,相较上年同比减少-59.25%;归属于上市公司股东的净利润1.06亿 元,同比减少91.49%;归属于上市公司股东的扣除非经常性损益的净利润-1.86亿元,同比减少 117.29%。 | | | | 甲 W: 儿 | 1114: Acch | | --- | --- | --- | --- | --- | | 主要会计数据 | 2024年 | 2023年 | 本期比上年 同期增减 | 2022年 | | | ...
哈药集团人民同泰医药股份有限公司2024年年度报告摘要
Shang Hai Zheng Quan Bao· 2025-04-11 20:25
Core Viewpoint - The company plans to retain undistributed profits for business development in 2025 and will not distribute profits or increase capital reserves for the current year [2][29]. Company Overview - The company operates in the pharmaceutical distribution industry, which is crucial for the national healthcare system and health industry, playing a vital role in the pharmaceutical supply chain [2]. - The company is the largest pharmaceutical distribution company in Heilongjiang Province, with a significant presence in both wholesale and retail sectors [12][13]. Industry Situation - The pharmaceutical distribution industry in China has shown stable growth, with the total sales scale reaching 2.93 trillion yuan in 2023, a year-on-year increase of 7.5% [3]. - The pharmaceutical wholesale market sales reached 2.29 trillion yuan in 2023, also reflecting a 7.5% year-on-year growth [4][5]. - The retail pharmaceutical market sales amounted to 640.2 billion yuan, with a year-on-year growth of 7.6% [6]. Industry Characteristics - The pharmaceutical distribution industry exhibits stable demand characteristics, with limited seasonal fluctuations and low sensitivity to macroeconomic cycles [8]. - The industry is characterized by regional differences, with companies that have strong distribution capabilities and a wide range of products enjoying competitive advantages [8]. Regulatory Environment - The government has introduced several reforms aimed at optimizing resource allocation and ensuring public medication safety, including centralized procurement and medical insurance payment reforms [9][10]. - The 2024 focus includes enhancing the transparency of drug pricing and promoting fair competition among pharmacies [9][10]. Company Financial Performance - In the reporting period, the company achieved operating revenue of 1,004.83 million yuan, a decrease of 3.29% year-on-year, and a net profit attributable to shareholders of 21.33 million yuan, down 27% year-on-year [19]. - The company's main business revenue was 1,000.72 million yuan, with wholesale business revenue of 822.80 million yuan and retail business revenue of 169.13 million yuan [19]. Business Operations - The company’s wholesale business primarily serves medical clients, including public hospitals and private medical institutions, while the retail business focuses on direct sales through chain pharmacies [14][16]. - The company has established strong partnerships with various pharmaceutical manufacturers, ensuring stable procurement channels [15].
人民同泰(600829) - 2024年度内部控制审计报告
2025-04-11 12:04
致同会计师事务所(特殊普通合伙) 中国北京 朝阳区建国门外大街 22 号 赛特广场 5 层 邮编 100004 电话 +86 10 8566 5588 传真 +86 10 8566 5120 www.grantthornton.cn 内部控制审计报告 致同审字(2025)第 210A009740 号 哈药集团人民同泰医药股份有限公司 二〇二四年度 内部控制审计报告 致同会计师事务所(特殊普通合伙) 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外, 由于情况的变化可能导致内部控制变得不恰当,或对控制政策和程序遵循的 程度降低,根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 Grant Thornton 致同 四、财务报告内部控制审计意见 我们认为,人民同泰公司于 2024 年 12 月 31日按照《企业内部控制基本 规范》和相关规定在所有重大方面保持了有效的财务报告内部控制。 哈药集团人民同泰医药股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求, 我们审计了哈药集团人民同泰医药股份有限公司(以下简称人民同泰公司) 2024 年 12 月 31 日的 ...
人民同泰(600829) - 2024年度审计报告
2025-04-11 12:04
哈药集团人民同泰医药股份有限公司 二〇二四年度 审计报告 致同会计师事务所(特殊普通合伙) 目 录 | 审计报告 | 1-6 | | --- | --- | | 合并及公司资产负债表 | 1-2 | | 合并及公司利润表 | 3 | | 合并及公司现金流量表 | 4 | | 合并及公司股东权益变动表 | 5-8 | | 财务报表附注 | 9-80 | 致同会计师事务所(特殊普通合伙) 中国北京朝阳区建国门外大街 22 号 赛特广场 5 层邮编 100004 电话 +86 10 8566 5588 传真 +86 10 8566 5120 www.grantthornton.cn 审计报告 致同审字(2025)第 210A009739 号 哈药集团人民同泰医药股份有限公司全体股东: 一、审计意见 我们审计了哈药集团人民同泰医药股份有限公司(以下简称人民同泰公 司)财务报表,包括 2024 年 12 月 31 日的合并及公司资产负债表,2024 年度的 合并及公司利润表、合并及公司现金流量表、合并及公司股东权益变动表以 及相关财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编 制,公允反 ...
人民同泰(600829) - 独立董事2024年度述职报告(武滨)
2025-04-11 12:04
一、独立董事情况 (一)独立董事的基本情况 武滨:1960 年生,研究生,高级咨询师,执业药师。曾任山西 省医药公司企业管理科副科长,山西省医药管理局商业处副处长,山 西省药材公司副经理,山西省医药集团有限公司经济运行部部长、总 经理助理,中国医药商业协会常务副会长;现任中国医药物资协会高 级顾问,中国医药企业管理协会专家委员会委员,老百姓大药房连锁 股份有限公司董事,亚宝药业集团股份有限公司董事,山东科源制药 股份有限公司董事,德展大健康股份有限公司独立董事,浙江维康药 业股份有限公司独立董事,本公司独立董事。 哈药集团人民同泰医药股份有限公司 独立董事 2024 年度述职报告 作为哈药集团人民同泰医药股份有限公司(以下简称"公司") 的独立董事,2024 年度我严格按照《中华人民共和国公司法》《中华人 民共和国证券法》《上市公司独立董事管理办法》及《公司章程》《独 立董事制度》等有关规定,忠实、勤勉地履行独立董事的职责,及时 了解公司运营情况,积极发挥独立董事的作用,认真审议各项议案, 独立客观地发表意见,审慎行使表决权,促进公司规范运作。依法维 护公司利益及全体股东特别是中小股东的合法权益。现将 202 ...
人民同泰(600829) - 独立董事2024年度述职报告(郭丹)
2025-04-11 12:04
(一)独立董事的基本情况 哈药集团人民同泰医药股份有限公司 独立董事 2024 年度述职报告 作为哈药集团人民同泰医药股份有限公司(以下简称"公司") 的独立董事,2024 年度我严格按照《中华人民共和国公司法》《中华人 民共和国证券法》《上市公司独立董事管理办法》及《公司章程》《独 立董事制度》等有关规定,忠实、勤勉地履行独立董事的职责,及时 了解公司运营情况,积极参加相关会议,认真审议各项议案,独立客 观地发表意见,审慎行使表决权,促进公司规范运作。依法维护公司 利益及全体股东特别是中小股东的合法权益。现将 2024 年度独立董 事的履职情况汇报如下: 郭丹:1970 年生,法学博士、教授、律师。曾任哈尔滨工业大 学法学院副院长、哈尔滨工业大学人文社科与法学学院法律系民商法 教研室主任;现任哈尔滨工业大学人文社科学部社会科学学院法律系 民商法教研室主任,黑龙江北大荒农业股份有限公司独立董事,江海 证券有限公司独立董事,本公司独立董事。 一、独立董事情况 (二)独立性的说明 在担任公司独立董事期间,本人未在公司担任除独立董事以外的 任何职务,也未在公司主要股东公司担任任何职务,与公司以及主要 股东之间不存在 ...